A large variety of mechanical systems is now available to support patients with ventricular dysfunctions which include: profound heart failure, lethal ventricular arrhythmias, cardiogenic shock, stone heart or stunned myocardium, following surgery. Their introduction in the treatment of patients initiated some 25 years ago and the development of clinical experience in the past 10 years today permits a reevaluation of the real problems faced by clinicians and engineers, leading to the suggestion of a reorientation of clinical research and technological development for the coming years. These problems may be grouped into seven chapters, the seven labors, imposed on Hercules in order to gain immortality.
The current experience in mechanical circulatory support may be grossly approached by analyzing the International Registry organized and updated every year by W. Pae and W. Pierce at Hershey. This Registry made up of voluntary reports is obviously not fully satisfactory per se. Nevertheless, it clearly shows that the systems have been used mostly as bridging devices either to the recovery of the native heart function (n = 1076 until 1992) or to a cardiac transplantation (n = 534). The overall success of the strategy is illustrated very simply by the number of patients actually being weaned off the device (46%) and the number of live patients being discharged from the hospital (25%) in the first group and by the number of patients being actually transplanted (67%) and becoming long term survivors (44%) in the second group. Analysis of risk factors points out the role of timing of the implantation, of severe associated organ dysfunction, of age and body weight and finally, in a few circumstances the role of the system itself: centrifugal pump assistance in patients unweanable off bypass offers the best chance for recovery. Implantable left ventricular devices allow a lower risk of transplantation. A second observation is related to the complications observed during the period of assistance. Problems related to thrombo-embolism or hemorrhage, to the natural evolution of the initial organ dysfunction and to infectious complications are by far the most critical issues, clearly reflecting the less than acceptable bio-compatibility of the materials. The almost unpredictable evolution of major organ dysfunction as restoration of an adequate arterial flow is achieved is another unsolved issue.
This short summary of the current experience, which has been previously analyzed more extensively suggests that major efforts should be pursued in many different directions to allow a real significant change in the role of mechanical assistance in the wide armentorium of techniques available today in cardiology. These are at least seven major issues, requiring efforts as intense as the seven labors given to Hercules.
The clinical issues
The clear definition of the final objective, the acceptability of the bridge to transplantation strategy itself, the adequate procedure of patient selection and the optimal choice, among the various systems available today, of the best one to reach the objective are definitely more complex issues than was expected a few years ago.
The first problem, which supposes the possibility of evaluating the real potential for recovery of a depressed myocardium is in most clinical cases an impossible challenge. Retrospective evaluation of clinical data does not allow definitive guidelines in the evaluation of the chances for myocardial recovery. In addition, the difference between the intention to treat and the actual observations is, too often, quite striking. The lack of a clear answer to this basic question leads to preferring systems which maintain relative flexibility for the potential to recovery, i.e. systems which do not require extreme manoeuvers such as cardiectomy.
The acceptability of the bridge to transplantation strategy should be discussed again. Most of the criticism about this approach in the past (waisting of organs for higher risk patients) have disappeared since the wide acceptance of contra-indications for transplantation in patients supported mechanically, and of the refusal of transplantation to avoid death on device. Re-evaluation of the actual number of possible transplantations, failure to sensitize the public to organ donation and in the mean time increasing numbers of candidates confirm, what was supported by some groups a few years ago, i.e. the bridge to transplantation strategy does not bring a satisfactory answer to the problem of organ shortage. This means that permanent and definitive implants have a role to play. Patient selection is an equally challenging problem. In the case of a patient in cardiogenic shock, admitted for mechanical assistance as an emergency procedure, the lack of time and the difficulties in communicating with a patient about to die may lead to options which eventually will appear inappropriate. Gaining time procedures such as the one offered by the optimization of sympathomimetic inotropic support, the addition of new inotropic agents (the pharmacological bridge) and/or the temporary use of easy to use, low cost systems (the bridge to the mechanical bridge) are at first glance attractive procedures. Nevertheless, they also have their limits and great care should be taken to avoid negative consequences of this initially acceptable approach.
Selection of the optimal system supposes an adequate answer to the previous questions. Ten years ago, every system, from the Jarvik total artificial heart to the bi-ventricular assist device appeared equally acceptable for apparently identical situations. It appears today that there are systems acceptable for immediate resuscitation and short term support (the hemopump, the centrifugal pump VAD's). There are, at the opposite end of the range, systems optimal for patients in profound left ventricular dysfunction, who need a prolonged support but at the time of implantation show still normal pulmonary vascular resistances and reversible organ dysfunction (the implantable left VAD's). Between these two extremes, there are indications for bi-ventricular external VAD's, pneumatically driven or orthotopical ventricles allowing either myocardial recovery or transplantation. Although this classification is obviously too schematic, it never-232 theless should help at the time of the decision.
Pathophysiological problems
There are still many probelms related to the consequences of the use of a mechanical device and to the evolution of various organ functions which remain unclear. In addition, biocompatibility of the system is quite unsatisfactory. Until now, most of the efforts have been directed toward more global issues such as transplantability, weaning and/or survival rates. Coagulation disorders related to the initial condition of low flow, to the use of the system and to the therapeutic manouvers employed to improve the hemocompatibility of the system deserve more detailed analysis. As usual in cardiac surgery, it seems that an empirical approach has permitted a fairly adequate solution. In addition, the alternative to the use of this type of unsatisfactory device is such (death) that less than acceptable solutions are accepted. Nevertheless, detailed analysis of the coagulation profile, of the pathological changes and of the surfaces of the system emphasize the need for in depth evaluation of this issue.
Some identical comments could be made on the infection issue and on the inflammatory response. As experience is growing the magnitude of the biocompatibility issue is also increasing. The long term consequences of the implantation of non biocompatible material may lead to an unknown situation: a "concrete" block in the mediastinum with a firm attachment of sclerotic tissue to an altered artificial ventricle.
The lack of strict parallelism between circulatory function improvement and lack of reversibility of organ dysfunction requires studies which are presently not directly in the sphere of activity and knowledge of standard cardiac surgeons. The responsability of the cardiac surgeon is therefore to attract the specialist of the various domains involved. Definition of strict indices of the various organ functions and propositon of a widely accepted scoring system should allow comparison of the experience in the various groups with various systems and lead to guidelines for the coming experience. Becoming a "maestro" capable of conducting this type of joint multi-disciplinary effort is not very easy for individuals such as surgical "divas". should help engineers in the design of systems more acceptable from anatomical, functional and surgical points of view. The lack of such precise information may be, for observers of the cardiac surgical community, quite astonishing, but unfortunately it is not far from the truth. Consequences may be catastrophic: a system which cannot achieve more than a 3.5 liter outflow should not be used in the same indication as a 12 liter pump. Likewise, design and manufacturing problems of a pump which will be used for a few hours or days are probably quite different than the development of a pump which is expected to maintain life during months or years and adjust to a mobile patient. Detailed analysis of the current experience, which allows more precise evaluation of the characteristics of the various categories of systems associated with the new tools available for the design and the manufacturing of prototypes, should allow a more rapid step-by-step evolution toward more adapted systems.
Industrial nightmare
How can we attract major industrial companies into the field of artificial heart technology, if the present situation is not clarified rapidly: who will invest in a product which is not clearly described, which is not precisely designed to fullfill the actual clinical needs and which will require months or years of development before reaching a market which may no longer exist. In addition, requirements such as zero default quality, redundancy of the critical parts, impose on the industry problems they do not necessarily seek. Finally, giving to the industry the exclusive responsability in case of dysfunction and detrimental consequences for the patient sets the standards at an unacceptable level. Again definition of clear and realistic objectives in a step by step approach should allow a real breakthrough.
Financial issues
At each level of the problem, in the engineering and technological aspects, in the animal evaluation procedures and in clinical use as well, the lack of appropriate solution to the real question: who will pay for the program? and how much? is a real limiting factor in the development of the clinical use of mechanical assistance based therapeutic strategies. In addition, this issue can not be extracted from the general economic context, which is not fully satisfactory, or from the other issues we are facing in medical care.
Clinicians may bring a tentative solution: the exact definition of the cost efficacy of a system, in a given, clearly defined indication, should lead to the reduction of the actual number of candidates. Integration of the mechanical support based strategy into the wide range of therapeutic actions which are now available should also minimize the real numbers, and consequently the total cost. Finally, breakthroughs in technology and rationalizaion of manufacturing procedures and improvement in the regulatory controls should contribute to reducing the extent of the problem.
Political issues
Political issues can not be ignored since they are the central prolem. Because life as a whole is, per se, the choice between various alternatives, everything is not possible. What should be placed first is difficult to establish: duration of life or quality of life? These existential issues have to be solved by politicians who are not necessarily experts in that field and who would probably prefer to focus on less dramatic and emotional issues, or who are driven by some type of geopolitical or personal concerns. To keep things simple, one may recall that competition between actions favorable to mankind and development of destructive techniques has been, since the bronze and the iron ages, not a scientific choice but a political responsability. We should always keep in mind the costs involved ion the development of the new tools of the star war ... and the minimal budget devoted to artificial hearts. Who will eventually force the politicians in their choice? It may be interesting to speculate on the fate of artificial heart programs in the early 60's if a maximum priority had been given to this field instead of to the project to land on the moon.
If emphasis is put on preservation of mankind's quality and duration of life, what should be supported first: preventive medicine or curative medicine? If we accept that limits of an effective preventive medicine are such that it is more useful to invest in curative medicine, what should be the first field to be served, cancer, AIDS or cardiology...? The fact that death due to a cardiac problem is more easily accepted than death by AIDS complication or cancer may misorient financial support toward non-cardiological research. In any case, it places the politicians in quite a comfortable situation.
Ethical dilemma
Doctors, administrators and Society can not avoid debates on the major ethical issues raised by the development of costly techniques, the sky rocketing pace of the evolution of health care costs. These ethical issues include also the preservation of the natural rights of an individual about to die: the choice between a quiet evolution to death, among relatives, avoiding major manoeuvers, as it was so nicely depicted in paintings and literature, or a risky fight for survival. Obviously the conflict between Society's concern, which includes in the mean time a control of expenses and the protection of its members, and the patient's own interest which may be to stay alive has to be solved.
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A broad approach, including efforts of engineers and industry to propose more acceptable options, efforts of clinicians by improved decisions in patient and device selection and in alternatives to mechanical assistance and efforts of politicians to increase the financial support should help to find acceptable proposals.
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